


Amendments to the Claims:

1-15. (Canceled)


16. (Previously Presented) A compound of formula (I)



wherein

---- represents a single or a double bond;

R is a radical selected from:



in which R_1 is halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

R_2 is hydrogen or C_{1-4} alkyl;

R_3 is hydrogen, hydroxy or C_{1-4} alkyl;

R_4 is hydrogen or R_4 together with R_3 is $=O$ or $=CH_2$;

R_5 is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_{1-4} alkyl, hydroxy, cyano, C_{1-4} alkoxy, trifluoromethoxy, halogen or $S(O)_q C_{1-4}$ alkyl;

R_6 and R_7 independently are hydrogen, cyano, C_{1-4} alkyl;

R_8 is $(CH_2)_r R_{10}$;

R₉ is hydrogen, halogen, C₃₋₇ cycloalkyl, hydroxy, nitro, cyano or C₁₋₄ alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C₁₋₄ alkoxy;

R₁₀ is hydrogen or C₃₋₇ cycloalkyl;

n is 1 or 2;


q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt or a solvate thereof.

17. (Previously Presented) A compound as claimed in claim 1 wherein n is 2.

18. (Previously Presented) A compound as claimed in claim 1 wherein R is:



wherein R₁ is halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3.

19. (Previously Presented) A compound as claimed in claim 1 wherein R₅ is phenyl or naphthyl optionally substituted by one or two groups selected from trifluoromethyl, cyano, C₁₋₄ alkyl or halogen.

20. (Previously Presented) A compound as claimed claim 1 wherein R₈ is (CH₂)_rR₁₀ wherein R₁₀ is hydrogen or C₃₋₇ cycloalkyl and r is 0 or 1.

21. (Previously Presented) A compound as claimed in claim 1, wherein R₉ is hydrogen or C₁₋₄ alkyl optionally substituted by one or two halogens.

22. (Previously Presented) A compound as claimed in claim 1 wherein:
R is phenyl substituted by a fluorine;
R₂, R₉ and R₄ are each hydrogen;
R₃ is hydrogen, hydroxy or methyl, or R₃ together with R₄ is =O or =CH₂;
R₆ and R₇ are independently hydrogen or methyl;
R₅ is phenyl or naphthyl optionally substituted by one or two groups independently selected from cyano, methyl, chlorine, bromine or fluorine atom;
R₈ is hydrogen, methyl or cyclopropylmethyl; and
n is 2.

23. (Previously Presented) A compound selected from:
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one;
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one ;
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);
1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one ;
1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one;
4-({3-[4-(4-Fluorophenyl)-4-piperidiny]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)methyl)-2-naphthalenecarbonitrile;
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);
1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one;
1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

- 1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;
- 1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);
- 1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;
- 4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl)methyl}-2-naphthalenecarbonitrile;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);
- 1-[(3-Chloro-1-naphthalenyl)methyl]-3-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;
- 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone
- 1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1);
- 1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone;
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);
- 1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);
7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl)-2-naphthalenecarbonitrile (Enantiomer 2);
6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl)-2-naphthalenecarbonitrile;
7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);
6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-2-oxo-1-pyrrolidiny)methyl)-2-naphthalenecarbonitrile (Enantiomer 1);
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1*H*-pyrrole-2,5-dione;
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-5-methylidene-1,5-dihydro-2*H*-pyrrol-2-one;
and pharmaceutically acceptable salts or solvates thereof.

24. (Previously Presented) A compound according to claim 23 in amorphous or crystalline form.

25. (Previously Presented) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one;
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride;
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one fumarate;
1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidiny]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

26. (Previously Presented) A compound according to claim 25 in crystalline form.

27. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2H-pyrrol-2-one citrate.
28. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2H-pyrrol-2-one.
29. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.
30. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 25 in admixture with one or more pharmaceutically acceptable carriers or excipients.
31. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 28 in admixture with one or more pharmaceutically acceptable carriers or excipients.
32. (Withdrawn) A method for the treatment of a psychotic disorder in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
33. (Withdrawn) A method for the treatment of depression or mood disorders in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
34. (Withdrawn) A method for the treatment of an anxiety disorder in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.

35. (Withdrawn) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 1.
36. (Withdrawn) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 25.
37. (Withdrawn) A method for treatment of rheumatoid arthritis in a mammal in need thereof, comprising administering an effective amount of a compound as claimed in claim 28.
38. (New) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidiny]-1,5-dihydro-2H-pyrrol-2-one or a pharmaceutically acceptable salt or a solvate thereof.
39. (New) A hydrochloride salt of the compound according to claim 38.
40. (New) A fumarate salt of the compound according to claim 38.
41. (New) A citrate salt of the compound according to claim 38.
42. (New) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

Two theta (deg)	d-spacing (Angstroms)
7,1	12,5
10,6	8,4
11,6	7,7
11,9	7,4
14,0	6,3
14,5	6,1
16,0	5,5
16,8	5,3
17,6	5,0
18,5	4,8
19,5	4,6
19,9	4,5
20,6	4,3
21,2	4,2
21,8	4,1
22,4	4,0
23,1	3,9
23,6	3,8

Two theta (deg)	d-spacing (Angstroms)
24,0	3,7
24,9	3,6
25,5	3,5
26,4	3,4
28,1	3,2
29,1	3,1
29,7	3,0
32,9	2,7

43. (New) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

d spacing Angstroms	Two Theta (deg)
7,7	11,5
7,2	12,2
5,5	16,1
5,3	16,7
5,0	17,6
4,8	18,6
4,6	19,4
4,2	21,1
3,9	23,1
3,8	23,6
3,6	24,5

44. (New) A crystalline hydrate of the compound according to claim 38.